Aberrations in oncogenic pathways and immune modulation influence treatment response in patients with metastatic leiomyosarcoma or liposarcoma.
The statistical significance of the improvements varied depending on how progression-free survival was measured.
CHICAGO – The benefit of trabectedin vs. best supportive care was entirely in patients with leiomyosarcoma or liposarcoma.
Regorafenib fell short of improving progression-free survival in patients with treatment-refractory liposarcomas, Richard Reidel, MD, of Duke...
Onodera’s Prognostic Nutritional Index in soft tissue sarcoma patients as a predictor of wound complications
Background The ability to predict a wound complication after radiation therapy and surgery for soft tissue sarcomas remains difficult....
IntroductionSoft tissue sarcomas (STSs) are rare adult tumors, with 3.4 new cases per 100,000 persons or 12,310 expected new cases in 2016.1...
Overall survival with eribulin was 15.6 versus 8.4 months with dacarbazine in a phase 3 randomized trial of 452 patients with advanced liposarcoma...